Cartesian Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $38.9M | $26.0M | $110.8M | $85.1M |
| Operating income | -$143.4M | -$43.9M | -$86.4M | $14.5M | -$4.6M |
| Operating expenses | $146.2M | $82.8M | $112.4M | $96.2M | $89.7M |
| Cash from operations | -$73.9M | -$23.7M | -$51.2M | -$31.6M | -$60.4M |
| Capital expenditure | $5.5M | $9.1M | $206,000 | $1.2M | $1.1M |
| Free cash flow | -$79.4M | -$32.8M | -$51.4M | -$32.8M | -$61.5M |
| Impairments | $0 | $7.6M | $710,000 | — | — |
| Total assets | $296.4M | $435.0M | $305.1M | $165.9M | $159.9M |
| Total liabilities | $422.7M | $441.8M | $444.7M | $72.1M | $137.4M |
Shares outstanding 29.4M · Free float 5.4%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.